2024

1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

   Blood, Vol. 143, Núm. 18, pp. 1807-1815

2. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes

   JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 60-72

3. Characterizing the “iceberg peak” in valvular heart disease: Outcomes and costs of in-hospital procedures in Spain

   REC: CardioClinics

4. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

   British Journal of Surgery, Vol. 111, Núm. 3

5. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

   Therapeutic Advances in Gastroenterology, Vol. 17

6. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

   Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723

7. Clinical practice guideline on the management of vestibular schwannoma

   Acta Otorrinolaringologica Espanola, Vol. 75, Núm. 2, pp. 108-128

8. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

   Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

9. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

   Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

10. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data

    Journal of the European Academy of Dermatology and Venereology

11. Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban

    Clinical Cardiology, Vol. 47, Núm. 2

12. Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial

    Haematologica, Vol. 109, Núm. 2, pp. 543-552

13. Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma

    Scientific Reports, Vol. 14, Núm. 1

14. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

15. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study

    European Journal of Heart Failure

16. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

17. Outcomes after surgical revascularization in diabetic patients

    Interdisciplinary cardiovascular and thoracic surgery, Vol. 38, Núm. 2

18. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics

19. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID)

    Surgical Oncology, Vol. 52

20. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1